Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Antiretroviral Neurotoxicity May Cause Cognitive Problems

As many as 50% of those on combination antiretroviral therapy (cART) suffer from mild to moderate cognitive dysfunction. Antiretroviral medications themselves may be partly to blame for such neurocognitive problems, suggests a recent review of previous studies. But the authors of this review do not recommend that antiretroviral treatment be stopped.

Published
28 January 2015
From
The Body Pro
Smoking is the main cause of increased risk of heart attack in people with HIV

People living with HIV who smoke have an almost three-fold greater risk of heart attack than HIV-negative smokers, according to Danish data published online ahead of print

Published
28 January 2015
By
Roger Pebody
Adherence packaging battles HIV/AIDS in Africa, India

Designed to help prevent the spread of HIV/AIDS in sub-Saharan Africa and India, MEMSCap smart electronic medication packaging system tracks each time the medication bottle is opened.

Published
26 January 2015
From
Packaging World
Why scientific AIDS explanations struggle in townships

HIV/AIDS educators often seem to enjoy raising an eyebrow at outlandish beliefs over the disease. But in doing so they fail to realise that the joke is on them – these ideas continue to hold sway despite their best efforts.

Published
26 January 2015
From
Africa Check
Bill Gates Predicts Two Miracles for AIDS Relief by 2030

Bill Gates said he expects a pair of advances by 2030 that will eliminate most of the damage from AIDS. Improved treatment and the development of a vaccine to prevent new infections are the “two miracles” needed to help turn the tide, the billionaire said Friday at the World Economic Forum in Davos, Switzerland.

Published
26 January 2015
From
Bloomberg
Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

Published
26 January 2015
From
Street Insider
Low CD4 count, suboptimal HIV treatment linked to higher anal cancer risk

People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.

Published
23 January 2015
From
HIVandHepatitis.com
Starting HIV treatment early and then interrupting is no better than delaying it

A French study that looked at the total amount of time since infection that people with HIV have spent with a detectable viral load has found that,

Published
22 January 2015
By
Gus Cairns
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire

Filter by country